Richard A Scolyer Selected Research

Nevus (Nevi)

4/2022	Expression of NGF/proNGF and Their Receptors TrkA, p75NTR and Sortilin in Melanoma.
1/2019	Molecular Genomic Profiling of Melanocytic Nevi.
3/2017	5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms.
7/2014	Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors.
11/2011	Selective loss of wild-type p16(INK4a) expression in human nevi.
8/2010	Diagnostic value of 8.5 T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies.
5/2010	IGFBP7 is not required for B-RAF-induced melanocyte senescence.
3/2010	State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop.
5/2008	Pathologic examination of sentinel lymph nodes from melanoma patients.
4/2007	Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard A Scolyer Research Topics

Disease

239	Melanoma (Melanoma, Malignant) 10/2022 - 08/2002
145	Neoplasms (Cancer) 10/2022 - 08/2002
56	Neoplasm Metastasis (Metastasis) 04/2022 - 10/2003
13	Nevus (Nevi) 04/2022 - 08/2002
10	Lymphatic Metastasis 04/2022 - 04/2004
8	Brain Neoplasms (Brain Tumor) 01/2022 - 05/2015
7	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2015 - 01/2004
7	Phyllodes Tumor (Cystosarcoma Phylloides) 12/2012 - 07/2002
6	Skin Neoplasms (Skin Cancer) 01/2022 - 02/2012
5	Uveal melanoma 04/2021 - 02/2014
5	Disease Progression 01/2020 - 01/2010
5	Margins of Excision 01/2019 - 04/2006
4	Neoplasm Micrometastasis 01/2022 - 07/2004
4	Blue Nevus 03/2017 - 11/2009
4	Tonsillar Neoplasms 11/2016 - 09/2003
4	Carcinogenesis 05/2015 - 02/2012
3	Extranodal Extension 01/2022 - 04/2012
3	Neuroblastoma 11/2017 - 02/2012
3	Dysplastic Nevus Syndrome (Dysplastic Nevus) 07/2014 - 06/2003
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2022
2	Hutchinson's Melanotic Freckle (Lentigo Maligna) 01/2022 - 11/2021
2	Pneumonia (Pneumonitis) 01/2022 - 05/2004
2	Hypothyroidism 01/2022 - 01/2021
2	Thyrotoxicosis 01/2022 - 01/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2021 - 07/2016
2	Colitis 11/2020 - 01/2019
2	Squamous Cell Carcinoma of Head and Neck 01/2019 - 10/2016
2	Breast Neoplasms (Breast Cancer) 01/2019 - 05/2009

Drug/Important Bio-Agent (IBA)

39	Biomarkers (Surrogate Marker)IBA 06/2022 - 09/2003
33	Proteins (Proteins, Gene)FDA Link 04/2022 - 07/2002
29	Immune Checkpoint InhibitorsIBA 05/2022 - 02/2015
23	DNA (Deoxyribonucleic Acid)IBA 08/2022 - 08/2002
22	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2022 - 03/2014
21	Biological ProductsIBA 10/2022 - 09/2003
15	ParaffinIBA 01/2022 - 02/2004
12	IpilimumabIBA 01/2022 - 12/2015
11	Formaldehyde (Formol)FDA Link 01/2022 - 12/2004
10	LigandsIBA 10/2022 - 12/2004
10	AntigensIBA 01/2022 - 05/2004
10	Phosphotransferases (Kinase)IBA 11/2017 - 08/2006
9	NivolumabIBA 01/2022 - 12/2015
8	pembrolizumabIBA 01/2022 - 12/2015
8	AntibodiesIBA 01/2022 - 06/2010
8	dabrafenibIBA 01/2019 - 03/2012
8	Pharmaceutical PreparationsIBA 01/2019 - 07/2004
8	MicroRNAs (MicroRNA)IBA 01/2017 - 09/2011
8	VemurafenibIBA 12/2015 - 03/2012
7	Eosine Yellowish-(YS) (Eosin)IBA 08/2022 - 09/2003
7	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2020
7	Circulating Tumor DNAIBA 01/2022 - 12/2015
7	Messenger RNA (mRNA)IBA 12/2021 - 09/2003
6	trametinibIBA 01/2019 - 12/2014
6	Cyclin D1IBA 10/2009 - 09/2003
5	Hematoxylin (Haematoxylon)IBA 08/2022 - 09/2003
5	EnzymesIBA 01/2019 - 09/2012
5	Cyclin-Dependent Kinase Inhibitor p16IBA 11/2011 - 09/2003
5	Protons (Proton)IBA 08/2010 - 06/2003
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 01/2010
4	CytokinesIBA 03/2021 - 03/2014
4	ChromatinIBA 01/2021 - 08/2002
4	ChemokinesIBA 01/2020 - 02/2008
4	Transcription Factors (Transcription Factor)IBA 01/2019 - 03/2012
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017 - 03/2014
4	Capsules (Microcapsules)IBA 04/2012 - 07/2004
4	Cell Cycle ProteinsIBA 10/2009 - 09/2003
4	AntimonyIBA 05/2008 - 03/2003
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2022 - 07/2004
3	MART-1 AntigenIBA 12/2021 - 09/2015
3	SuspensionsIBA 01/2021 - 06/2010
3	Niacinamide (Nicotinamide)FDA LinkGeneric 02/2020 - 10/2015
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2018 - 01/2013
3	CateninsIBA 12/2017 - 01/2014
3	Mitogen-Activated Protein KinasesIBA 11/2017 - 04/2014
3	B7-H1 AntigenIBA 11/2017 - 07/2016
3	5-hydroxymethylcytosineIBA 03/2017 - 09/2012
3	Adenosine (Adenocard)FDA LinkGeneric 01/2017 - 12/2009
3	Glucose (Dextrose)FDA LinkGeneric 07/2015 - 03/2009
3	Cadherins (E-Cadherin)IBA 05/2013 - 04/2003
2	Imiquimod (Aldara)FDA LinkGeneric 01/2022 - 11/2021
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2021 - 10/2006
2	Histones (Histone)IBA 01/2021 - 01/2013
2	Melanins (Melanin)IBA 12/2020 - 11/2009
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2020 - 05/2004
2	Codon (Codons)IBA 01/2019 - 02/2014
2	GTP Phosphohydrolases (GTPases)IBA 01/2019 - 12/2018
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2018 - 04/2003

Therapy/Procedure

91	Therapeutics 09/2022 - 05/2004
55	Immunotherapy 10/2022 - 09/2012
27	Lymph Node Excision (Lymph Node Dissection) 01/2022 - 07/2004
8	Radiotherapy 01/2022 - 06/2007
7	Neoadjuvant Therapy 08/2022 - 01/2019
6	Precision Medicine 07/2022 - 12/2012
6	Drug Therapy (Chemotherapy) 10/2021 - 01/2017
5	Adjuvant Radiotherapy 11/2017 - 09/2008
4	Aftercare (After-Treatment) 05/2022 - 03/2012
3	Chemoprevention 02/2020 - 10/2015
3	Molecular Targeted Therapy 01/2020 - 01/2008
2	Ambulatory Care (Outpatient Care) 01/2022 - 05/2021
2	Metastasectomy 10/2021 - 08/2013
2	Neck Dissection (Radical Neck Dissection) 12/2019 - 04/2004